Optimark™ ,gadoversetamide injection
Focused on Patients, Focused on Clinical Efficacy, Focused on Efficiency
Optimark™ gadoversetamide injection is the only gadolinium-based contrast agent (GBCA)approved for administration by a power injector by the U.S. Food and Drug Administration (FDA)1. Convenient packaging options include our exclusive Ultraject™ prefilled syringes to help reducethe potential for medication errors, help meet stringent regulatory requirements, possibly reduce the risk of infection, and improve efficiency2.
Optimark™ injection is a non-ionic, extracellular GBCA with roughly half the osmolality of the U.S. FDA-approved ionic GBCAs. It is also considered a lower viscosity GBCA which helps to facilitate the use of smaller caliber needles and lower pressures for patient administration.6
Optimark™ injection provides statistically significant improvement over baseline for conspicuity, border delineation, and confidence in number of lesions in Central Nervous System (CNS) and liver studies1.
At Covidien we have made a commitment to help the physician community leverage medical innovation, information and insight to address patient care issues. We have established a specific email contact to address any questions as they pertain to NSF (email@example.com) as well as provided links to pertinent information from both internal and external sources (on the right side of this page). We’ve also included a link to the presentation "NSF Focus on Patient Safety", adapted from the presentation given at RSNA 2008 by Covidien Imaging Solutions' Chief Medical Officer Herbert Neuman, MD, and our field sales representatives can provide a leader-led course, titled "Magnetic Resonance Imaging Safety Update May 2008" which is an ASRT-CE accredited course. Information and education can help reduce NSF risk. We are committed to ongoing research, product innovation and professional education that results in enhanced patient care.